Use of <scp>S</scp>orafenib as an effective treatment in an <scp>AML</scp> patient carrying a new point mutation affecting the <scp>J</scp>uxtamembrane domain of <i><scp>FLT</scp>3</i>
Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Rosa Ayala(Hospital Universitario 12 De Octubre), Carlos Grande(Research Institute Hospital 12 de Octubre), Nerea Castro(Hospital Universitario 12 De Octubre), Alicia Canal(Universidad Complutense de Madrid), Daniel Rueda(Research Institute Hospital 12 de Octubre)
Cited by 5
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523